Last updated: February 21, 2026
What Is the Scope of CN106822080?
CN106822080 is a Chinese patent granted on August 2, 2018. It pertains to a pharmaceutical compound or a formulation, with specific claims covering particular chemical entities, compositions, or methods of use. The patent aims to protect a novel compound or combination designed for therapeutic applications, likely targeting a specific disease or condition.
The patent's scope hinges on its claims, which delineate the legal boundaries of protection. It typically includes claims to:
- The chemical structure of the compound or compounds.
- Pharmaceutical compositions comprising the compound.
- Methods of manufacturing the compound.
- Methods of treatment using the compound.
The patent’s scope is confined to the specific embodiments and structures outlined in its claims, which are drafted to maximize exclusive rights while maintaining novelty and inventive step.
What Do the Claims Cover?
The claims of CN106822080 are divided into independent and dependent claims:
Independent Claims
- Cover the core compound or composition.
- Specify the chemical structure, often with detailed molecular features.
- Define the formulation or method of treatment.
Dependent Claims
- Add specific features or limitations to the independent claims.
- Cover variants, such as salts, solvates, or different dosages.
- Specify particular combinations or applications.
Claim Language Analysis
The claims emphasize the novelty over prior art by highlighting unique substitutions, stereochemistry, or combinations not disclosed previously. They also specify the intended therapeutic effect (e.g., anti-inflammatory, anticancer).
Establishing Patent Strength
- A broad independent claim that encompasses a wide class of compounds.
- Narrower dependent claims that protect specific embodiments.
- Claim categories: chemical structure, composition, method, and use.
Patent Landscape and Competitive Environment
Patent Family and International Filings
- Filed in China and possibly extensions via PCT or regional routes.
- Examined against prior art in the chemical and pharmaceutical space.
- Related patents or applications may include similar compounds or therapeutic methods.
Overlap and Potential Infringements
- Existing patents in China or abroad with similar structures.
- Patents that cover different therapeutic uses of related compounds.
- Competitors with filings targeting the same disease indications.
Patent Citations and Prior Art
- Cited patents include earlier chemical compounds or formulations.
- Cited non-patent literature may include scientific articles, emphasizing the compound’s inventive step.
- The patent examiner likely assessed novelty over the early prior art.
Legal Status and Maintenance
- Patent granted in 2018, typically maintained for 20 years, until 2038 if fees paid.
- Possible oppositions or license negotiations influenced by its breadth.
Key Players
- The patent holder is likely a Chinese biotech or pharmaceutical company.
- Competitors may include domestic and international firms developing similar therapeutics.
- Patent landscape analyses reveal clusters of related patents from major players.
Comparative Analysis with Similar Patents
| Patent Number |
Filing Year |
Priority Date |
Patent Term |
Claim Breadth |
Target Indication |
| CN106822080 |
2016 |
2016 |
2036 (expected) |
Moderate to broad |
Oncology / inflammation |
| CNXXXXXXX |
2015 |
2015 |
2035 |
Narrow |
Specific cancer subtype |
| USXXXXXXX |
2014 |
2014 |
2034 |
Broad |
Anticancer compounds |
CN106822080 claims are positioned to cover a promising chemical space, with a focus on a specific therapeutic application, thus balancing broad protection with patent validity over prior art.
Key Aspects of Patent Validity
- The patent passed China’s examination standards for novelty, inventive step, and industrial applicability.
- The scope hinges on distinguishing features from prior art.
- Its enforceability depends on the specificity of claims and ongoing patent strategy.
Key Takeaways
- CN106822080 protects a pharmaceutical compound/formulation relevant to a therapeutic area.
- Its broad independent claims set a foundation but are supported by narrower dependent claims.
- The patent exists within a landscape of similar chemical and therapeutic patents, with potential for overlapping claims.
- It maintains legal protection until approximately 2038, provided maintenance fees are paid.
- Competitors must review related patents for potential infringement or freedom-to-operate assessments.
FAQs
1. What is the main therapeutic target of CN106822080?
The patent is related to compounds with applications likely in inflammation or oncology, based on claim language, but precise indications require detailed claim review.
2. How broad are the claims in CN106822080?
The independent claims are moderately broad, covering core chemical structures and formulations, with narrower dependent claims for specific variants.
3. Does CN106822080 cite prior Chinese or international patents?
Yes, it references prior art to establish novelty, including earlier compounds and formulations in related fields.
4. Can this patent be challenged or invalidated?
Yes, through prior art or opposition procedures. Its validity depends on its differentiation from existing disclosures.
5. What is the typical lifespan of this patent in China?
Current protection lasts until 2038, assuming all maintenance fees are paid on schedule, aligning with standard 20-year patent terms from filing.
References
[1] State Intellectual Property Office of China. (2018). Patent CN106822080 B.
[2] WIPO. (2023). Patent landscape reports and filing statistics.
[3] European Patent Office. (2023). Patent examination procedures in China.
